Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 May 28;172(10):799-809.
doi: 10.1001/archinternmed.2012.402.

Subclinical hyperthyroidism and the risk of coronary heart disease and mortality

Affiliations
Review

Subclinical hyperthyroidism and the risk of coronary heart disease and mortality

Tinh-Hai Collet et al. Arch Intern Med. .

Abstract

Background: Data from prospective cohort studies regarding the association between subclinical hyperthyroidism and cardiovascular outcomes are conflicting.We aimed to assess the risks of total and coronary heart disease (CHD) mortality, CHD events, and atrial fibrillation (AF) associated with endogenous subclinical hyperthyroidism among all available large prospective cohorts.

Methods: Individual data on 52 674 participants were pooled from 10 cohorts. Coronary heart disease events were analyzed in 22 437 participants from 6 cohorts with available data, and incident AF was analyzed in 8711 participants from 5 cohorts. Euthyroidism was defined as thyrotropin level between 0.45 and 4.49 mIU/L and endogenous subclinical hyperthyroidism as thyrotropin level lower than 0.45 mIU/L with normal free thyroxine levels, after excluding those receiving thyroid-altering medications.

Results: Of 52 674 participants, 2188 (4.2%) had subclinical hyperthyroidism. During follow-up, 8527 participants died (including 1896 from CHD), 3653 of 22 437 had CHD events, and 785 of 8711 developed AF. In age- and sex-adjusted analyses, subclinical hyperthyroidism was associated with increased total mortality (hazard ratio[HR], 1.24, 95% CI, 1.06-1.46), CHD mortality (HR,1.29; 95% CI, 1.02-1.62), CHD events (HR, 1.21; 95%CI, 0.99-1.46), and AF (HR, 1.68; 95% CI, 1.16-2.43).Risks did not differ significantly by age, sex, or preexisting cardiovascular disease and were similar after further adjustment for cardiovascular risk factors, with attributable risk of 14.5% for total mortality to 41.5% forAF in those with subclinical hyperthyroidism. Risks for CHD mortality and AF (but not other outcomes) were higher for thyrotropin level lower than 0.10 mIU/L compared with thyrotropin level between 0.10 and 0.44 mIU/L(for both, P value for trend, .03).

Conclusion: Endogenous subclinical hyperthyroidism is associated with increased risks of total, CHD mortality, and incident AF, with highest risks of CHD mortality and AF when thyrotropin level is lower than 0.10 mIU/L.

PubMed Disclaimer

Figures

Figure
Figure
Total mortality, coronary heart disease (CHD) mortality, CHD events, and atrial fibrillation in endogenous subclinical hyperthyroidism vs euthyroidism. Age and sex-adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs) are represented by squares or diamonds, those to the right of the solid line indicate increased risk. The sizes of data markers are proportional to the inverse of the variance of the HRs. *Forty-one participants were excluded from the analyses of CHD mortality because of missing cause of death. †The Birmingham Study, HUNT (Nord-Trøndelag Health Study), SHIP (Study of Health in Pomerania), and Brazilian Thyroid Study were not included because follow-up data were only available for death. EPIC indicates European Prospective Investigation of Cancer.

Comment in

Similar articles

  • Subclinical hypothyroidism and the risk of coronary heart disease and mortality.
    Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO, Iervasi G, Imaizumi M, Collet TH, Bremner A, Maisonneuve P, Sgarbi JA, Khaw KT, Vanderpump MP, Newman AB, Cornuz J, Franklyn JA, Westendorp RG, Vittinghoff E, Gussekloo J; Thyroid Studies Collaboration. Rodondi N, et al. JAMA. 2010 Sep 22;304(12):1365-74. doi: 10.1001/jama.2010.1361. JAMA. 2010. PMID: 20858880 Free PMC article.
  • Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation.
    Baumgartner C, da Costa BR, Collet TH, Feller M, Floriani C, Bauer DC, Cappola AR, Heckbert SR, Ceresini G, Gussekloo J, den Elzen WPJ, Peeters RP, Luben R, Völzke H, Dörr M, Walsh JP, Bremner A, Iacoviello M, Macfarlane P, Heeringa J, Stott DJ, Westendorp RGJ, Khaw KT, Magnani JW, Aujesky D, Rodondi N; Thyroid Studies Collaboration. Baumgartner C, et al. Circulation. 2017 Nov 28;136(22):2100-2116. doi: 10.1161/CIRCULATIONAHA.117.028753. Epub 2017 Oct 23. Circulation. 2017. PMID: 29061566 Free PMC article. Review.
  • Subclinical thyroid dysfunction and fracture risk: a meta-analysis.
    Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Åsvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Jüni P, Aujesky D, Rodondi N; Thyroid Studies Collaboration. Blum MR, et al. JAMA. 2015 May 26;313(20):2055-65. doi: 10.1001/jama.2015.5161. JAMA. 2015. PMID: 26010634 Free PMC article.
  • Thyroid status, cardiovascular risk, and mortality in older adults.
    Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW. Cappola AR, et al. JAMA. 2006 Mar 1;295(9):1033-41. doi: 10.1001/jama.295.9.1033. JAMA. 2006. PMID: 16507804 Free PMC article.
  • [Subclinical hyperthyroidism].
    Feldkamp J. Feldkamp J. Dtsch Med Wochenschr. 2013 Oct;138(42):2146-50. doi: 10.1055/s-0033-1343278. Epub 2013 Jul 19. Dtsch Med Wochenschr. 2013. PMID: 23873176 Review. German.

Cited by

References

    1. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228–238. - PubMed
    1. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab. 2005;90(1):581–587. - PubMed
    1. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76–131. - PubMed
    1. Bahn RS, Burch HB, Cooper DS, et al. American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593–646. - PubMed
    1. Biondi B. Endogenous subclinical hyperthyroidism: who, when and why to treat. Expert Rev Endocrinol Metab. 2011;6(6):785–792. - PubMed

Publication types

MeSH terms

Grants and funding